Phase III Study of ASP2151 in Herpes Simplex Patients; A Double-blind, Placebo-controlled Study
Phase of Trial: Phase III
Latest Information Update: 23 May 2016
Price : $35 *
At a glance
- Drugs Amenamevir (Primary)
- Indications Herpes genitalis; Herpes labialis; Herpes simplex virus infections
- Focus Therapeutic Use
- Sponsors Maruho
- 15 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 13 Apr 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Apr 2015 as reported by ClinicalTriasl.gov record.
- 13 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTriasl.gov record.